Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

When Gallbladder Disease on Ozempic (Semaglutide 0.5 to 2 mg) Becomes a Reason to Stop

By
Published Updated Last reviewed
7 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Suspected gallstones or cholecystitis / Gallbladder studies are indicated [1]
  • Confirmed gallbladder disease / the label gives no stopping rule [1]
  • Suspected acute pancreatitis / Discontinue Ozempic and start appropriate management [1]
  • Gallbladder disorders in SELECT / 2.8% vs 2.3% on placebo [2]
  • Gallbladder disorders across GLP-1 trials / up 26% vs control in a 21-trial meta-analysis [3]

What the Ozempic label says about gallbladder disease

Acute gallbladder disease has its own entry in the Ozempic warnings, and the action it specifies is diagnostic: if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]. The Ozempic and Rybelsus tablet label uses the same wording [4]. Cholecystitis and cholecystectomy also appear among the postmarketing reports in the Ozempic label [1].

The stop rule that does apply: suspected pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Ozempic [1]. The label says possible signs are persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue Ozempic and initiate appropriate management [1].

Postmarketing reports in the Ozempic label include acute and necrotizing pancreatitis, sometimes fatal [1].

How often gallbladder problems occurred

In SELECT, 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes received semaglutide 2.4 mg or placebo [5]. Gallbladder-related disorders occurred in 2.8% versus 2.3% (p=0.04), driven mainly by cholelithiasis (1.4% versus 1.1%), while cholecystitis rates were equal at 0.6% versus 0.6% [2].

Across the drug class, a meta-analysis of 21 randomized trials covering 99,599 patients and eight different GLP-1 receptor agonists found gallbladder disorders increased by 26% compared with controls [3]. A separate meta-analysis of once-weekly semaglutide in adults with overweight or obesity but no diabetes reported an odds ratio of 2.06 for cholelithiasis [6].

Does switching drugs avoid the problem?

The 21-trial meta-analysis found gallbladder disorders up 26% across eight GLP-1 receptor agonists pooled together [3]. For tirzepatide, a 2023 meta-analysis of nine trials with 9,871 participants found a significantly higher risk of the combined gallbladder or biliary disease outcome (RR 1.97, 95% CI 1.14 to 3.42) versus placebo or basal insulin, although cholelithiasis and cholecystitis analyzed separately were not significantly increased [7].

Frequently asked questions

Does the Ozempic label say to stop if I have gallstones?
The label's instruction for suspected cholelithiasis or cholecystitis is that gallbladder studies are indicated, which is investigation rather than a stopping rule [1]. Its explicit discontinue instruction in this area is for suspected pancreatitis [1].
How common are gallbladder problems on semaglutide?
In SELECT, gallbladder-related disorders occurred in 2.8% on semaglutide 2.4 mg versus 2.3% on placebo, mainly cholelithiasis at 1.4% versus 1.1%; cholecystitis was 0.6% in both groups [2]. Across 21 trials of GLP-1 receptor agonists, gallbladder disorders were 26% more frequent than with control [3].
What symptoms does the Ozempic label list for pancreatitis?
The label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting [1].
Is tirzepatide gentler on the gallbladder?
A 2023 meta-analysis of nine tirzepatide trials with 9,871 participants found a higher risk of the combined gallbladder or biliary disease outcome (RR 1.97, 95% CI 1.14 to 3.42) versus placebo or basal insulin, with no significant increase for cholelithiasis or cholecystitis analyzed separately [7].

References

  1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  2. Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025;33(3):452-462. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
  3. Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
  4. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
  5. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
  6. Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(9):e13792. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials
  7. Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Evidence overview for When Gallbladder Disease on Ozempic (Semaglutide 0.5 to 2 mg) Becomes a Reason to Stop